Summary
This Form 8-K filing by Eli Lilly and Company on December 15, 2015, announces a significant change in its Board of Directors. Effective February 1, 2016, Juan R. Luciano will join the Board. Mr. Luciano brings extensive executive experience, currently serving as the CEO and President of Archer Daniels Midland Company (ADM), and previously holding senior roles at ADM and The Dow Chemical Company. His appointment is strategic, with Mr. Luciano expected to contribute to the Public Policy and Compliance Committee and the Finance Committee. This addition to the Board signifies a potential infusion of new perspectives and expertise, particularly in areas critical to corporate governance and financial oversight. Investors should note that Mr. Luciano will stand for election by shareholders at the May 2016 annual meeting, and his compensation will follow the established director compensation program.
Key Highlights
- 1Eli Lilly & Co. elected Juan R. Luciano as a new member to its Board of Directors, effective February 1, 2016.
- 2Juan R. Luciano currently serves as CEO and President of Archer Daniels Midland Company (ADM).
- 3Mr. Luciano has a strong background in the chemical industry, with a 25-year tenure at The Dow Chemical Company.
- 4He will serve on the Public Policy and Compliance Committee and the Finance Committee.
- 5Mr. Luciano was selected without any pre-existing arrangements, and is not involved in any reportable transactions with the company.
- 6He will participate in the standard director compensation program as outlined in the company's 2015 Proxy Statement.
- 7The appointment was accompanied by a press release filed as an exhibit to this 8-K.